Longeveron to Present at Longevity Leaders World Congress; Latinos and Alzheimer’s Symposium; International Frailty and Sarcopenia Research Conference

ByLois C

Apr 18, 2022 , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,


April functions to spotlight Longeveron’s determination to establishing cell therapeutics for chronic ageing related conditions.

MIAMI, April 14, 2022 (World NEWSWIRE) — Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Firm”), a scientific stage biotechnology organization acquiring mobile therapies for long-term, growing older-linked and everyday living-threatening situations, declared these days its Main Science Officer, Co-Founder, and Chairman, Joshua Hare, M.D., F.A.C.C., F.A.H.A. will be presenting at the Longevity Leaders World Congress in April. Also this thirty day period, Longeveron Director of Healthcare Affairs Kevin N. Ramdas, M.D. M.P.H. will present at the future 12th Annual International Meeting on Frailty and Sarcopenia Exploration (ICFSR) as effectively as the 3rd Once-a-year Latinos & Alzheimer’s Symposium hosted by the Alzheimer’s Association, the place Longeveron’s Senior Scientist, Anthony Oliva, PhD will also reasonable and current two oral communications.

Information of Longeveron’s participation at these occasions are as follows:

  • 12th Yearly International Meeting on Frailty and Sarcopenia Analysis (ICFSR)
    Title: Biomarker Results from a Section 2b Clinical Trial Examining Lomecel-B Infusion in Older Adults with Frailty
    Format: Live oral presentation by Kevin N. Ramdas, M.D., M.P.H., Director of Medical Affairs
    Day: April 20, 2022
    Time: 4:20 p.m. ET
    Area: Boston, Massachusetts

  • 12th Annual Intercontinental Convention on Frailty and Sarcopenia Analysis (ICFSR)
    Title: Lomecel-B as a Geroscience Therapeutic Prospect for Cognitive Frailty
    Structure: Moderating and presentation by Anthony A. Oliva, PhD, Senior Scientist
    Date: April 21, 2022
    Time: 12:00 p.m. ET
    Locale: Boston, Massachusetts

  • 3rd Latinos & Alzheimer’s Symposium
    Title: Range, equity and inclusion in a section 1 medical trial assessing Lomecel-B in sufferers with Alzheimer’s condition
    Format: Poster session introduced by Kevin N. Ramdas, M.D., M.P.H., Director of Health-related Affairs
    Poster Quantity: 68512
    Day: April 25, 2022
    Time: 12:45 ET
    Locale: Bonita Springs, Florida

  • Longevity Leaders Entire world Congress
    Title: Advancing getting older frailty by means of the clinic with ageing clinical endpoints
    Structure: Live oral presentation by Joshua Hare, M.D., F.A.C.C., F.A.H.A., Co-Founder, Chief Science Officer, and Chairman
    Date: April 26, 2022
    Time: 1:40 p.m. GMT (9:40 a.m. ET)
    Place: London, United Kingdom

  • Longevity Leaders World Congress
    Title: Translating and commercializing regenerative medicine and ageing science into therapeutics and customer products and solutions
    Format: Live panel with participation from Joshua Hare, M.D., F.A.C.C., F.A.H.A., Co-Founder, Main Science Officer, and Chairman
    Date: April 26, 2022
    Time: 3:45 p.m. GMT (10:45 p.m. ET)
    Site: London, United Kingdom

About Longeveron Inc.
Longeveron is a medical phase biotechnology organization acquiring cellular therapies for particular getting older-associated and lifestyle-threatening situations. The Company’s direct investigational item is the LOMECEL-B™ cell-centered treatment product (“Lomecel-B”), which is derived from lifestyle-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of youthful, healthy grownup donors. Longeveron thinks that by employing the similar cells that advertise tissue fix, organ maintenance, and immune method purpose, it can build safe and efficient therapies for some of the most hard conditions related with the ageing system and other health-related disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Ageing Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). The Company’s mission is to advance Lomecel-B and other cell-primarily based product candidates into pivotal Section 3 trials, with the target of achieving regulatory approvals, subsequent commercialization, and wide use by the healthcare group. Extra details about the Enterprise is available at www.longeveron.com.

Brendan Payne
Stern Investor Relations
Tel: (212) 362-1200
E-mail: [email protected]

Supply: Longeveron

By Lois C